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Abstract
Background: Acetaminophen (N-acetyl-para-aminophenol) is the most widely used
over-the-counter or prescription painkiller in the world. Acetaminophen is metabolized
in the liver where a toxic byproduct is produced that can be removed by conjugation
with glutathione. Acetaminophen overdoses, either accidental or intentional, are the
leading cause of acute liver failure in the United States, accounting for 56,000
emergency room visits per year. The standard treatment for overdose is
N-acetyl-cysteine (NAC), which is given to stimulate the production of glutathione.
Methods: We have created a mathematical model for acetaminophen transport and
metabolism including the following compartments: gut, plasma, liver, tissue, urine. In
the liver compartment the metabolism of acetaminophen includes sulfation,
glucoronidation, conjugation with glutathione, production of the toxic metabolite, and
liver damage, taking biochemical parameters from the literature whenever possible.
This model is then connected to a previously constructed model of glutathione
metabolism.
Results: We show that our model accurately reproduces published clinical and
experimental data on the dose-dependent time course of acetaminophen in the
plasma, the accumulation of acetaminophen and its metabolites in the urine, and the
depletion of glutathione caused by conjugation with the toxic product. We use the
model to study the extent of liver damage caused by overdoses or by chronic use of
therapeutic doses, and the effects of polymorphisms in glucoronidation enzymes. We
use the model to study the depletion of glutathione and the effect of the size and
timing of N-acetyl-cysteine doses given as an antidote. Our model accurately predicts
patient death or recovery depending on size of APAP overdose and time of treatment.
Conclusions: The mathematical model provides a new tool for studying the effects of
various doses of acetaminophen on the liver metabolism of acetaminophen and
glutathione. It can be used to study how the metabolism of acetaminophen depends
on the expression level of liver enzymes. Finally, it can be used to predict patient
metabolic and physiological responses to APAP doses and different NAC dosing
strategies.
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Background
Acetaminophen (N-acetyl-para-aminophenol, APAP or paracetamol) is the most widely
used over-the- counter and prescription painkiller in the world [1]. While safe at ther-
apeutic doses of up to 4 grams per day for adults, acetaminophen overdoses, either
accidental or intentional, are the leading cause of acute liver failure in the United States,
accounting for some 56,000 emergency room visits, 2,600 hospitalizations and nearly 500
deaths annually [2,3].
Acetaminophen is metabolized by conjugation with sulfate and glucoronidate, which
are inert and are excreted in the urine. Depending on dose, a fraction of APAP is con-
verted into a highly reactive toxic intermediate, N-acetyl-p-benzoquinone imine (NAPQI)
by several P450 cytochromes [4]. Substantial amounts of NAPQI are effectively elimi-
nated by conjugation with glutathione (GSH). However, after a large dose of APAP, the
sulfonation reaction becomes saturated and the build up of NAPQI depletes GSH in the
liver, causing further accumulation of NAPQI. Unconjugated NAPQI binds to proteins
and subcellular structures and induces rapid cell death and necrosis that can lead to liver
failure. Themain biochemical pathways of acetaminophenmetabolism and the transports
between various compartments are pictured in Figure 1.
N-acetylcysteine (NAC) can be an effective antidote for APAP poisoning. NAC limits
hepatotoxicity by increasing GSH synthesis in the liver [5]. Current protocols recommend
treating patients with an initial dose of 150 mg/kg NAC, infused over a period of an hour,
upon hospitalization, followed by decreasing amounts of NAC infused over the next 20
hours [1]. Fatal liver damage can be prevented if the initial dose of NAC is administered
within 8-12 hours of an APAP overdose. This antidote dosage regime has been developed
empirically over a period of many years based on outcomes from clinical cases. It is not
known whether the current NAC treatment protocol is optimal.
Figure 1 Acetaminophenmetabolism. Blue boxes indicate substrates: APAP, acetaminophen; APAP-S,
APAP-sulfonate; APAP-G, APAP-glucoronidate; NAPQI, N-acetyl-p-benzoquinone imine; NAPQI-COV, covalent
binding of NAPQI; NAPQI-GSH, NAPQI conjugated with glutathione; PAPS, 3’-Phosphoadenosine-5’-
phosphosulfate; GSH, glutathione. The light orange ovals indicate the enzymes that catalyze reactions: SULT,
sulfotransferase; UGT, glucuronosyltransferase; CYP, cytochrome P-450 oxidase; GST, glutathione S-transferase.
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The metabolism of APAP has been well-studied and the distributions of its metabolites
in the plasma and urine of humans are well-documented [4,6,7], as are the hepatic values
in mice and rats [8]. What has been lacking is an integrated and quantitative understand-
ing of the kinetics of APAP metabolism, of how APAP dosage affects NAPQI synthesis
and GSH concentrations in the liver, of how NAC stimulates the synthesis of GSH, and
of how the dosage and timing of NAC affect detoxification of NAPQI. In this paper we
develop a mathematical model for APAPmetabolism that allows us to study, in silico, how
various doses of APAP are metabolized and whether or not a dose exceeds the capac-
ity of the liver to synthesize sufficient GSH. In order to study how the metabolism of
APAP affects GSH concentration and resynthesis, we have connected the model depicted
in Figure 1 to our extant model of glutathione metabolism [9]. This enables us to exam-
ine the effect of GSH synthesis capacity on the ability of hepatocytes to detoxify NAPQI,
the accumulation of NAPQI-induced liver damage, and the effects of different doses and
timing of NAC in emergency departments.
Remien et al. [10] recently developed a mathematical model to estimate overdosage of
APAP based on indicators of liver damage (blood levels of aspartate aminotransferase,
alanine aminotransferase and the international normalized ratio of prothrombin time)
that are measured upon admission to hospital emergency departments. In a retrospective
study, this model was able to accurately predict whether the overdose would lead to fatal
liver damage. Our model is complementary to the work of [10] since it focuses on the
detailed biochemical mechanisms by which of APAP is detoxified in the liver under both
normal and overdose situations.
Methods
The mathematical model consists of 21 differential equations for the variables listed in
Table 1. The differential equations corresponding to the reactions diagramed in Figure 1
are listed below. Lower case p, l, t, and u refer to plasma, liver, tissue and urine respec-
tively. We use lower case italic abbreviations in the differential equations and other
formulas so that they are easy to read and are not confused with enzyme names which
are in caps. Full names for the enzymes appear in the legend to Figure 1. Reaction veloc-
ities or transport velocities begin with a capital V followed by the name of the enzyme,
the transporter, or the process as a subscript. For example, VlSULT(lapap, lpaps) is the
velocity of the sulfation reaction in the liver, which depends on the concentrations of
the substrates, lapap and lpaps. After the differential equations, we discuss in detail the
more difficult modeling issues and reactions with non-standard kinetics. Table 2 gives the
assumed values of volumes, transport parameters, and hepatocyte parameters. Table 3
gives the parameter choices and references for biochemical reactions.
The differential equations for the variables listed in Table 1 are:
d[ gapap]
dt = −kgl · gapap
d[ papap]
dt = ktp · (vT/vP) · tapap−kpt · papap+klp · (vL/vP) · lapap − kpu · papap
d[ pas]
dt = kslp · (vL/vP) · las + kstp · (vT/vP) · tas − kspu · pas
d[ pag]
dt = kglp · (vL/vP) · lag + kgtp · (vT/vP) · tag − kgpu · pag
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Table 1 Names used for Variables
In equations In text Full name
gapap gAPAP APAP in the gut
papap pAPAP APAP in the plasma
pas pAPAP-S APAP sulfonate in the plasma
pag pAPAP-G APAP glucoronidate in the plasma
pnqgsh pNAPQI-GSH NAPQI-GSH complex in the plasma
lapap lAPAP APAP in the liver
lpaps lPAPS liver phosphoadenosine-phosphosulfate
las lAPAP-S APAP sulfonate in the liver
lag lAPAP-G APAP glucoronidate in the liver
lnq lNAPQI NAPQI in the liver
lcov covalent binding covalent binding of NAPQI in the liver
lnqgsh lNAPQI-GSH NAPQI-GSH complex in the liver
lgsh lGSH GSH in the liver
lh lH functional hepatocytes
lz lZ damaged hepatocytes
tapap tAPAP APAP in the tissue
tpaps tPAPS tissue phosphoadenosine-phosphosulfate
tas tAPAP-S APAP sulfonate in the tissue
tag tAPAP-G APAP glucoronidate in the tissue
uapap uAPAP APAP in the urine
uas uAPAP-S APAP sulfonate in the urine
uag uAPAP-G APAP glucoronidate in the urine
unq uNAPQI NAPQI in the urine
unqgsh uNAPQI-GSH NAPQI-GSH complex in the urine
d[ pnqgsh]
dt = knqglp · (vL/vP) · lnqgsh − knqgpu · pnqgsh
d[ lapap]
dt = kgl · (vG/vL) · gapap + kpl · (vP/vL) · papap − VCYP(lapap)
− VlSULT(lapap, lpaps) − VlUGT(lapap)
d[ las]
dt = VlSULT(lapap, lpaps) − kslp · las
d[ lag]
dt = VlUGT(lapap) − kglp · lag
d[ lnq]
dt = VCYP(lapap) − VGST(lnq, lgsh) + krev · lcov − kbind · lnq
d[ lcov]
dt = kbind · lnq − krev · lcov
d[ lh]
dt = r · lh · (1 −
(lh + lz)
hmax
) − η · lcov · lh
d[ lz]
dt = η · lcov · lh − δz · lz
d[ lpaps]
dt = Vlpaps − VlSULT(lapap, lpaps) − klpaps · lpaps
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Table 2 Parameters (μM,μM/hr,/hr)








kgl 4 APAP from gut to liver
kpt 0.39 APAP from plasma to tissue
ktp 0.78 APAP from tissue to plasma
kpl 0.0225 APAP from plasma to liver
klp 0.2025 APAP from liver to plasma
kslp 0.24 sulfonate from liver to plasma
kstp 0.0913 sulfonate from tissue to plasma
kglp 0.3024 glucoronidate from liver to plasma
kgtp 0.5171 glucoronidate from tissue to plasma
knqglp 0.3 NAPQI-GSH conjugate from liver to plasma
kpu 0.06 APAP from plasma to urine
kspu 4 sulfonate from plasma to urine
kgpu 3.8 glucoronidate from pasma to urine
knqgpu 0.4 NAPQI-GSH conjugate from plasma to urine
ku 1.54 urine elimination
Hepatocyte parameters
r .0417 logistic growth (hr−1)
hmax (1.6)1011 maximum hepatocyte number
η (.213)10−4.2 cell death rate due to NAPQI (hr−1μM−1)
δz .2083 removal of dead hepatocytes (hr−1)
d[ tapap]
dt = kpt · (vB/vT) · papap − ktp · tapap − VtSULT(tapap, tpaps)
− VtUGT(tapap)
d[ tas]
dt = VtSULT(tapap, tpaps) − kstp · tas
d[ tag]
dt = VtUGT(tapap) − kgtp · tag
d[ tpaps]
dt = Vtpaps − VtSULT(tapap, tpaps) − ktpaps · tpaps
d[uapap]
dt = kpu · (vB/vU) · papap − ku · uapap
d[uas]
dt = kspu · (vB/vU) · pas − ku · uas
d[uag]
dt = kgpu · (vB/vU) · pag − ku · uag
d[unqgsh]
dt = knqgpu · pnqgsh − ku · unqgsh
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Table 3 Biochemical Parameters (μM,μM/hr,/hr)






Km 3430 3430-3440 [16]
Vmax 0.55
VCYP2E1 cytochrome CYP2E1
Km 677 677-1260 [16]
Vmax 345
VCYP3A4 cytochrome CYP3A4
Km 276 276-313 [16]
Vmax 0.99
V(l/t)SULT sulfation
Kapapm 97 97 [24]
Kpapsm 5.6 5.6 [25]
Vmax in liver 1785
Vmax in tissue 357
PAPS metabolism
Vlpaps (synthesis liver) 0.1
klpaps (linear removal) 0.0033
Vtpaps (synthesis tissue) 0.01
ktpaps (linear removal) 0.00033
VGST glutathione transferase






V(l/t)UGT = VUGT1 + VUGT2 +
VUGT3 + VUGT4
VUGT1 glucoronidation
Km 5500 5500 [20]
n (Hill) 3.2
Vmax in liver 6370
Vmax in tissue 1274
VUGT2 glucoronidation
Km 4000 4000 [20]
Ki 23000 23000 [20]
Vmax in liver 490
Vmax in tissue 98
VUGT3 glucoronidation
Km 9200 9200 [20]
Vmax in liver 4900
Vmax in tissue 980
VUGT4 glucoronidation
Km 23000 23000 [20]
Ki 5300 5300 [20]
Vmax in liver 7350
Vmax in tissue 1470
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Absorption and dosing
APAP is absorbed from the gut into the portal circulation which flows into the liver. In
our model, our oral doses are deposited in the gut compartment and then removed and
put into the liver with linear kinetics. In [11] the half life for gastric emptying was calcu-
lated to be 7 minutes for oral liquid doses and overnight fasting. We take the linear rate
constant to be 4μM/hr, which gives a half-life of approximately 10 minutes, since absorp-
tion will be slower with pills and non-fasted state. Most of the dose is absorbed in 30 to
60 minutes. The bioavailability of APAP is known to vary considerably depending on age,
method of administration, and gut contents. An early study [12] measured an average
bioavailability of 79% and a recent study [13] found a range 63%–89%. We assume that
the bioavailability of a dose is 75%. A standard therapeutic dose is variously reported as
1000 mg or 20 mg/kg. In our model, we assume a 60 kg individual and a dose of 20mg/kg,
which would make that standard dose 1200 mg. To convert those values to molarity in
the gut we assumed a gut volume of 1 liter; then a 20 mg/kg dose (the typical therapeutic
dose) produces a gut concentration of 6000 μM, assuming 75% bioavailability.
Cytochrome oxidase
Many P450 enzymes catalyze the production of NAPQI fromAPAP [14,15]. In our model,
NAPQI is produced in the liver by three cytochrome oxidases, CYP2E1, CYP3A4, and
CYP1A2.We assume each isMichaelis-Menten and take theKm values from [16]. Cyp3A4









Allosteric activation, including substrate activation, of P450 enzymes has been exten-
sively documented [17-19]. We have included substrate activation (the Hill term on the
right) and found that if we omitted this substrate activation then the cytochrome oxidase
reactions did not produce enough NAPQI at high overdoses.
Glucoronidation
There are four glucoronosyltransferases, UGT 2B15, UGT 1A1, UGT 1A6, UGT 1A9 (that
we denote simply by UGT1, UGT2, UGT3, and UGT4), that glucoronidate APAP. Each
has somewhat different kinetics with different parameters: UGT3 has simple Michaelis-












Km4 + (lapap)(1 + lapapKi4 )
Glutathione synthesis andmetabolism
We use a previously published model of liver glutathione metabolism [9]. That model is
connected to the model for APAP metabolism described here by adding the reaction by
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whichGSH conjugates NAPQI via the enzymeGST. This enables us to study how different
doses of APAP decrease liver GSH and how that affects the formation of NAPQI. We take
the Km of GST for GSH to be 5200 μM, midway between the values 4500 [21] and 5600
[22], Km = 15μM for NAPQI, and Vmax = 72, 000μM/hr.
Sulfation
APAP can be detoxified by being sulfated in a reaction with PAPS [23]. We take the reac-
tion to have standard bi-bi kinetics with Km = 97μM for APAP [24] and Km = 5.6μM for
PAPS [25].
Covalent binding
NAPQI is believed to exert its toxic effects by binding covalently to liver proteins leading
to protein denaturation and necrosis of liver cells [6,26,27]. We model the reaction as
linear and reversible because covalent binding of NAPQI gradually declines after eight
hours [28,29].
Hepatic necrosis
The rate at which functional hepatocytes are damaged is proportional to the product
of the number of functional hepatocytes and the concentration of covalent binding of
NAPQI. We use the differential equations for the rate of change of the number of living
hepatic cells and the rate of change of the number of damaged cells from [10].
Transport
There are few measurements of overall transport rates of the metabolites between the
compartments of the model. We chose to make all transport rates linear and adjusted
them so that the measured APAP, APAP-S, APAP-G, and NAPQI-GSH concentrations in
the plasma and the urine were as measured in the literature [4,6,11,30-32]. Values of the
transport coefficients are given in Table 2.
Results
Model comparison to experimental data
We modeled an oral dose of APAP by setting an initial value in the gut compartment.
From the gut compartment, the dose first enters the liver where some of it is metabolized
and conjugated, and the rest enters the general circulation from where it is taken up by
liver and tissues or excreted in the urine. The profile of APAP and its glucoronidate and
sulfate conjugates in the plasma after a 20 mg/kg dose were studied in [4] and are shown
in Figure 2B, and the results computed by our model for the same dose are shown in
Figure 2A. The match to the experimental data is excellent.
It is known that high doses of APAP are toxic for two reasons. First, the sulfonation
reaction saturates and that allows more NAPQI to accumulate ([7,24]) and second, the
increased amount of NAPQI exhausts the liver stores of reduced glutathione (GSH) [6]
as well as the liver’s capacity to synthesize new GSH. In Figure 3, we show model com-
putations of the rates of the glucoronidation reaction, the sulfation reaction and the
cytochrome P450 reaction in the liver at 0.5 hours after the dose for a range of doses.
The sulfonation reaction saturates at relatively modest doses, but the rates of the glu-
coronidation reaction and the rate of formation of NAPQI by the P450 reaction increase
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Figure 2 Times courses in the plasma. Panel A shows model calculations of the time courses of APAP,
APAP-S, and APAP-G in the plasma after an APAP dose of 20mg/kg. Panel B shows the values measured in
the plasma redrawn from Prescott et al. [4].
monotonically with dose. The dramatic increase in the synthesis of NAPQI is seen in
Figure 4 where we plot the velocities as a percentage of their value relative to those com-
puted at a standard dose. In Figure 5 we show the millimoles of APAP, APAP-S, and
APAP-G that accumulate in the urine over a 24-hour period in the model for a range of
doses. These elimination rates correspond well with the data in [7].
Figure 3 Liver reaction velocities as function of dose. Panel A shows the sum of the rates of the
glucoronidation reactions in the liver 0.5 hours after the dose for a range of doses. The normal dose is 20
mg/kg assuming a 60 kg individual. Similarly, Panels B and C show the rates of the sulfation reaction and the
sum of the P450 reactions, respectively. The sulfation reaction saturates at relatively modest doses.
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Figure 4 Liver reaction velocities as percent of velocities for a therapeutic dose. The velocities of the
glucoronidation, sulfation, and P450 reactions are shown as a percentage of the velocities for a normal dose
of 20 mg/kg at 0.5 hours after the dose. Note the steep rise of the P450 reactions as the dose increases.
Figure 5 Accumulation of metabolites in the urine. Panels A, B, and C show the accumulation of APAP,
APAP-S, and APAP-G, respectively, in the urine over a 24 hour period as a function of APAP dose. The results
correspond well to those reported in [7]. We give the dose in moles for easy comparison to the experimental
data.
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Mitchell et al. [6] measured the level of GSH depletion in the liver (of mice), and the
amount of covalent binding of radiolabeled APAPmetabolites (later identified as NAPQI)
in the liver after a wide range of doses of APAP. They showed that doses above 400 mg/kg
caused an almost complete exhaustion of GSH levels in the liver and a sharp rise in the
amount of covalent binding (Figure 6B). We used our model for APAP metabolism, inte-
grated with our model for GSH metabolism [9] to compute the concentration of hepatic
GSH and the amount of covalent binding of NAPQI after various doses of APAP. These
model results are shown in Figure 6A and show a close similarity to the experimental
results of [6] shown in Figure 6B. Mitchell et al. [6] reported covalent binding in units of
nanomoles per milligram protein, whereas in our program we calculate NAPQI covalent
binding in units of molarity. In Figure 6B we scale our units so they are “2” at dose of 833
mg/kg so they correspond numerically to the values given by Mitchell et al. [6] and are
more easily compared.
Effect of chronic dosing
The recommended therapeutic dose of APAP is 1000 mg not more than four times per
day ([33,34]). In Australia and new Zealand, the recommended dose is 500 to 1000 mg
every four to six hours, not to exceed 4000 mg per day [1]. In the USA, the maximum
dosage per day recommended by the manufacturer (MacNeil Consumer Healthcare)
was reduced from 4000 mg (eight 500 mg pills) to 3000 mg (six 500 mg pills) in
2011 [35].
Although high doses of APAP are well known to be associated with increased risk of
liver failure, chronic exposure to standard therapeutic doses is also not without risk. For-
get et al. [36] report on two cases of acute liver failure after 3 and 10 days of therapeutic
APAP treatment, respectively, in patients with liver steatosis. Nuttall et al. [37] studied
the effect of chronic ingestion of therapeutic doses of APAP (1 gram, 4 times per day,
for 2 weeks) on serum antioxidant capacity, and found a gradual and progressive decline
to a level about 85% of control value. Part of the antioxidant capacity of serum is due to
the presence of GSH and the reduced capacity could be associated with a general reduc-
tion in GSH due to its conjugation with NAPQI. Watkins et al. [38] studied the effect of
Figure 6 Glutathione depletion and covalent binding. Panel A shows model results. The blue curve
shows the liver GSH concentration as a percentage of normal (left scale) 2 hours after the a dose of APAP as a
function of dose size. The red curve shows the concentration of covalent binding of NAPQI (right scale)
scaled to equal 2 at extremely high doses for easy comparison with the results of Mitchell et al. [6]. Panel B
shows the comparable experimental results redrawn from [6] for the same two quantities.
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chronic APAP ingestion (using the same protocol of 1000 mg every 6 hours for 14 days)
on liver damage as measured by elevation of serum alanine aminotransferase (ALT). They
found ALT elevations of up to 8 times the upper limit of normal in 8% of participants,
and three times the upper limit of normal in 39% of participants. This study was stopped
early due to the frequency and magnitude of the elevation in ALT in the treatment group
relative to controls, although none of the participants expressed symptoms of liver dis-
ease. In a prospective study, Sabate et al. [39] estimated the incidence of acute liver injury
due to therapeutic dosages of APAP to be about 10 per million user-years. These stud-
ies show that chronic usage of APAP at recommended therapeutic levels probably does
mild liver damage and may be associated with a reduction in GSH levels that compromise
antioxidant defense capacity.
We used our model to study the effect of repeated doses of APAP on liver and serum
GSH levels, NAPQI binding and estimated liver damage. We computed the effect of
a 1000 mg dose every 6 hours for a period of 10 days. In our simulations (Figure 7,
panels A and B) liver GSH declines to 70% of normal and plasma GSH declines to 88% of
normal. These new dynamic steady states are achieved after about 150 hours. In compar-
ison, Nuttall et al. [37] found that antioxidant capacity of serum continued to decline for
2 weeks and declined to 85% of normal. In Figure 7C we show an estimate of liver dam-
age done by these chronic doses. The estimate of liver necrosis is rather small, less that
0.05% damage, and this may be sufficient to account for the elevation of ALT observed
by Watkins et al. [38], and the absence of symptoms of liver disease after chronic usage.
The GSH curves oscillate because of the discrete dosing every six hours and the regener-
ation of GSH in the liver. The liver necrosis curve oscillates because cells that die during a
dose are replaced by regenerated cells; we take the regeneration rate from [10]. Ourmodel
simulations suggest that chronic usage of APAP at recommended therapeutic levels prob-
ably does mild liver damage and may be associated with a reduction in GSH levels that
compromise antioxidant defense capacity.
Effect of drugs that affect P450 activity
The toxicity of acetaminophen is due to the action of several P-450 cytochromes (CYPs)
that catalyze the synthesis of NAPQI from APAP. The activity of these enzymes is
enhanced by a variety of chemicals, including caffeine [40,41] and anticonvulsant drugs
[42], and it is well known that co-ingestion of these drugs with APAP can greatly enhance
the toxicity of APAP.
A relationship between the consumption of ethanol and the toxicity of APAP has also
long been known [43]. In rats and mice, chronic exposure to alcohol causes an increased
expression of CYP-2E1 and increases the activity of the enzyme 5- to 7-fold [44,45]. In
humans the effect is much less dramatic, and alcohol consumption causes a transient two-
fold induction of CYP-2E1 ([43,46]). The role of alcohol in enhancing the toxic effects of
APAP is variable and acute alcohol doses may have different effects on P-450 induction
than chronic exposure to alcohol [43]. Exposure of cultured human hepatocytes to alcohol
increased the expression of CYP-2E1 and CYP-3A3/4 up to 6-fold, but the effect appeared
to be individually variable [47].
We used our model to study the effect of increased activity of the P450 enzymes on
the level of NAPQI covalent binding and the predicted associated level of hepatic cell
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Figure 7 Glutathione depletion and hepatic necrosis under chronic therapeutic dosing. Panels A, B,
and C show the model computations liver GSH, plasma GSH, and liver necrosis as a result of therapeutic
dosing of APAP(1 gram every 6 hours) for 10 days. The curves reach their new steady states after about 150
hours. The curves oscillate because of the period dosing of APAP, the resynthesis of GSH in the liver, and
regeneration of cells in the liver.
necrosis. In Figure 8 we show the effect of two-fold and four-fold increases in P450 activity
on NAPQI covalent binding at different doses of APAP. Covalent binding increases with
APAP dose and with P-450 activity and the increase is non-linear. Doses of 2 to 4 times
the therapeutic dose have only small effects, but the effect increases rapidly with doses
above 8 times the normal therapeutic dose if P-450 activity is elevated.
Prescott [43] has suggested that increased APAP toxicity in the presence of alcohol may
occur only when the liver is already compromised by other factors. Our finding that there
is only a small increase increase in covalent binding after a therapeutic dose, even with a
four-fold increase in CYP P-450 activity supports this idea.
Ben-Shachar et al. Theoretical Biology andMedical Modelling 2012, 9:55 Page 14 of 22
http://www.tbiomed.com/content/9/55
Figure 8 The effects of APAP dose and CYP activity on covalent binding and necrosis. Panel A: Model
computations show the effect of P450 activity on liver necrosis at 12 hours after APAP doses of various sizes
(normal, green; twice normal, blue; four times normal, red). Liver failure is thought to occur when the percent
of functional hepatocytes falls below 30% [10]. Panel B: Model computations of the effect of of P450 activity
on the covalent binding of NAPQI at 12 hours after APAP doses of various sizes (normal, green; twice normal,
blue; four times normal, red). For relatively modest doses, P450 activity has little effect in both cases.
However, the effect of P450 activity is dramatic for high doses.
Effects of polymorphisms in glucoronosyl transferases
There are two reasons to expect that the glucoronosyl tranferase enzymes may be crucial
for preventing liver damage. First, as we have shown above in Figures 4 and 5, the sulfa-
tion reaction saturates at fairly lowAPAP doses because of the low concentration of PAPS.
Second, although the conjugation of the toxic intermediate NAPQI by glutathione is an
important protectivemechanism, it occurs after the production of NAPQI, while glucoro-
nidation removes APAP before the production of NAPQI. Furthermore, a large number of
genetic variants have been described in the UGT genes that are due to mutations in both
the coding and regulatory regions of the genes [48-53]. These genetic variants are com-
mon and can have profound effects on the APAP glucoronidation capacity of the liver. For
instance, Fisher et al. [48] found up to 7-fold differences in the rates of APAP glucoronida-
tion in a sample of 20 human livers, and Court et al. [54] found 15-fold inter-individual
variability in APAP glucoronidation rates in liver microsomal fractions.
We used our model to test the importance of glucoronidation and it’s sensitivity to the
activity of the glucoronosyl tranferase enzymes by computing the amount of liver damage
resulting from amoderate overdose (10 g) with different choices for theVmax values of the
glucoronosyl tranferases. With the normal values (given in Methods) of Vmax for the four
glucoronosyl tranferases, there is almost no liver damage (the black curve in Figure 9).
When the Vmax values are set to 50% of their normal values, the number of functional
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Figure 9 Polymorphisms in glucoronosyl transferases affect liver damage.Many polymorphisms in
glucoronosyl tranferase enzymes reduce their activity by 50% or more (see text). The black, blue, and red
curves show model calculations of the time courses of the percentage of functional hepatocytes in response
to a 10 g overdose if the Vmax for the four glucoronosyl tranferases are normal (as given in Methods), 50% of
normal, or 10% of normal, respectively. The activity of the glucoronosyl tranferases has a dramatic effect on
liver damage. With normal parameter values (black curve) there is almost no hepatocyte death. However, at
the 10% level (red curve), the number of functional hepatocytes decreases well below the 30% level thought
to be the threshold for liver failure [10].
hepatocytes decreases to 75% of normal after 20 hours (the blue curve). And, when the
Vmax values are set to 10% of their normal values, the number of functional hepatocytes
decreases to 10% of normal after 40 hours (the red curve), well below the grey barmarking
30% remaining hepatocytes, which is thought to be the threshold for liver failure [10].
Glutathione depletion and N-acetylcysteine rescue
Since the purpose of NAC rescue is to replenish GSH in the liver, it is important to know
the time course of GSH in reponse to various doses and how quickly it recovers. Because
our acetaminophen model is connected to our GSH model we can compute these time
courses explicitly. In Figure 6 we showed that an overdose of APAP (corresponding to
200 mg/kg, or a 12 g dose for a 60 kg person) depletes liver GSH severely after 2 hours.
Figure 10 shows the time-line of decline and recovery of hepatic GSH after a therapeutic
dose (1 g), and after 5 g, 10 g, 15 g, and 20 g doses, respectively. The 20 g dose is borderline
lethal without NAC rescue. The reduction in hepatic GSH after a therapeutic dose is
minor, but a 15 g dose almost completely depletes hepatic GSH between 2 and 10 hours.
For the 20 g dose, liver GSH does not start to recover until 40 hours after the dose. In all
cases, including a therapeutic dose, it takes more than 48 hours for GSH to recover to its
original steady-state. In the cases of 15 g and 20 g doses the liver concentration of GSH
stays very low for an extended period of time. This does not mean that conjugation of
NAPQI is not taking place. NAPQI is being conjugated at the rate at which new GSH is
being synthesized, which keeps the concentration of GSH from rising.
The literature on NAC rescue for acetaminophen overdose makes it clear that early res-
cue is important [10,55,56]. We used the model to investigate the effect of the timing of
N-acetylcysteine (NAC) rescue. We assume a 22 g dose of APAP followed by an infusion
of 36 mM NAC (the standard rescue dose [1]) over a 1 hour period starting at various
times after the APAP dose. The black curve in Figure 11 shows the time course of the per-
centage of functional hepatocytes after the 22 g dose. It decreases well below the shaded
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Figure 10 Liver GSH depletion and recovery. The black, blue, magenta, green, and red curves show liver
GSH depletion and recovery after a therapeutic dose (1 g) of APAP, and after 5 g, 10 g, 15g, and 20 g doses,
respectively. Liver GSH is almost completely depleted between 2 hours and 10 hours after the 15 gram dose
and after 48 hours liver GSH has recovered only to about 1/2 of normal. Even for the therapeutic dose, liver
GSH has not completely recovered after 48 hours.
horizontal bar that represents 30% hepatocytes left, the level below which liver failure is
thought to occur [10]. The green curve shows the time course of the percentage of func-
tional hepatocytes if the NAC rescue is performed at 2 hours after the dose was ingested;
the curve stays well above the 30% level. The blue, red, cyan, and magenta curves show
the time courses of the percent functional hepatocytes if the rescue dose is given at 6, 10,
Figure 11 Time course of the percent functional hepatocytes after a 22 g overdose and different NAC
rescue times. The black curve shows model computations of the percentage of function hepatocytes after
an 22 g dose of APAP. The curve decreases well below the gray bar at the 30% level below which liver failure
usually occurs. The green curve shows the time course of functional hepatocytes with rescue by 36 mM NAC
given continuously for one hour starting at 2 hours after the overdose. The green curve stays well above the
30% threshold. The blue, red, cyan, and magenta curves show the time courses of functional hepatocytes if
the rescue dose is given at 6, 10, 14, 18 hours respectively. The curves show clearly the importance of early
rescue.
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14, 18 hours respectively. The cyan curve is borderline for liver failure and the magenta
curve is well below the 30% bar. Notice that in all cases the percentage of functional hep-
atocytes continues to decrease for some time after the NAC rescue. These curves show
clearly the importance of early NAC dosing for saving patients. Of course, with a smaller
overdose, the curves would be higher and with a larger overdose the curves will be lower.
We used the model to test how sensitive the model is to the size of the NAC rescue
dose. In Figure 12, the black curves show the GSH concentration in the liver (Panel A)
and the fraction of functional hepatocytes as a function of time (Panel B) after a 22 g dose
of APAP. The dashed black curves show the responses of GSH and fractional hepatocytes
to rescue by the standard dose of NAC (36 mM) given over a 1 hour time period starting
at two hours after the APAP dose. We refer to this rescue as protocol 1. With this early
rescue dose, the patient likely survives because the dashed black curve in Panel B stays
well above the 30% level for functional hepatocytes, which is thought to indicate liver
failure. Other curves show the responses to giving different amounts of NAC over this one
hour period. Doubling the amount of NAC (dashed green) has very little effect on rescue
Figure 12 The effects of different NAC doses and rescue protocols on liver GSH and functional
hepatocytes. Panel A shows time courses liver GSH concentrations and Panel B shows time courses of
functional hepatocytes. For all simulations the APAP dose was 22g, which is lethal without NAC rescue. The
black curves show the time course of liver GSH and functional hepatocytes with no NAC rescue. The dashed
black curves show the effects of rescue with a dose of 36mM NAC given over a one hour period starting two
hours after the APAP dose (protocol 1). If we rescue over one hour with twice as much NAC (green dashed
curves) or half as much NAC (solid red curves) the results are very similar. However, rescue with 1/10 (solid
blue curves) and 1/20 (solid green curves) the normal NAC dose over a one hour period starting at 2 hours
show much poorer rescue; at 1/20 the patient’s hepatocytes decline to 30% and survival is in doubt. The
dashed red curves and the blue dashed curves show the time courses of liver GSH and functional
hepatocytes corresponding to the dosing protocols 2 and 3 as described in the text. In these protocols, the
NAC dose is spread out over time. Protocol 3 is better than protocol 2, which is better than protocol 1.
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and neither does halving the amount of NAC (solid red). However, 1/10 the normal NAC
rescue (solid blue) and 1/20 the normal NAC rescue (solid green) substantially delay the
time of GSH rebound and decrease substantially the curves showing the time course of
functional hepatocytes. At 1/20 the normal rescue dose, the hepatocyte curve descends
to the 30% level so the survival of the patient is unclear.
We also simulated the effect on hepatic GSH level and functional hepatocytes of two
other dosing protocols. In protocol 2, we give 3.6 mM of NAC per hour for 10 hours
beginning 2 hours after the 22 g APAP dose. Thus, the total amount of NAC infused was
identical to the standard amount given in a 1 hour-infusion (protocol 1). Our simulations
(red dashed curve in Figure 12) show that protocol 2 does better than protocol 1: the red
dashed curves are higher than the black dashed curves. Finally, we simulated the NAC
dosing protocol recommended in [1], which we refer to as protocol 3. This protocol con-
sists of infusing half the 36 mM NAC dose over a 1-hour period starting at 2 hours after
the APAP dose, followed by 1/6 of the dose over the next 4-hour period and then 1/3 of
the dose over an additional 16 hours. The blue dashed curves in Figure 12 show the time
course of GSH (Panel A) and the time course of functional hepatocytes (Panel B) for pro-
tocol 3. Protocol 3 is substantially better than protocol 2, which is better than protocol 1.
Predicted death or recovery
Remien et al [10] developed a model that allowed them to use patient values of plasma
indicators of liver damage (plasma levels of aspartate aminotransferase, alanine amino-
transferase, and the international normalized ratio of prothrombin time) to estimate the
APAP dose and the time of dose. Their model then calculates a prediction of death or
recovery using using 30% remaining hepatocytes as the boundary between death and
recovery. They compared their model with the patient records of 53 patients at the Uni-
versity of Utah Medical Center and their predictions of death or recovery were quite
accurate. To compare the predictions of our model to the patient records, we used their
predictions of size and timing of dose for each of the 53 patients. Then we computed using
our model whether the functional hepatocytes ever declined below 30% in which case we
predict death rather than recovery. Figure 13 shows the outcome for the 53 patients in
the study of Remien et al. [10]; blue indicates recovery, red indicates death, and each dot
is plotted so that the x-coordinate is the Remien-predicted dose and each y coordinate
is the Remien-predicted time since dose when the patient appeared in the Emergency
Department. In Figure 13, the medium grey line shows the coordinates that result in 30%
remaining hepatocytes. Thus our model predicts recovery to the left of the medium gray
line and death to the right of the medium gray line. For reference, the curves for 35%
remaining hepatocytes (light grey) and 25% remaining hepatocytes (dark grey) are also
shown. Our model predicts outcomes very well; only two of our predicted recoveries died
and three of our predicted deaths survived.
Discussion
We have created a whole body model of acetaminophen transport and metabolism that
includes the details of the biochemical pathways of acetaminophen metabolism in the
liver and peripheral tissues. The model was based as much as possible on parameters
from the biochemical literature. When compared to experimental and clinical data on
the accumulation of the byproducts of acetaminophen metabolism, APAP-S, APAP-G,
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Figure 13 Predicted death or recovery. Each dot represents one patient (who did not receive a liver
transplant) and it is plotted so that the x coordinate is the dosage estimated by Remien et al. [10] and the y
coordinate is the time since the dose estimated by Remien et al. [10]. Death or recovery is indicated by red or
blue, respectively. We indicate the curve of hepatocyte depletion to 35% of normal (light grey), 30% of
normal (medium grey), and 25% of normal (dark grey). If we use the 30% curve as the boundary between
predicted death and predicted recovery, then we incorrectly predict only 3 deaths and 2 recoveries.
and NAPQI-GSH, in the plasma and in the urine of humans, the model gives accurate
predictions (see Figures 2, 3, 4 and 5).
We connected the whole body model of acetaminophen metabolism to our previously
constructed model of glutathione metabolism [9] so that we could study the depletion
of GSH after APAP doses of various sizes (Figure 6). We found that therapeutic doses
decrease liver GSH by only modest amounts (10%), but that overdoses of 10 grams or
more severely deplete liver GSH (Figure 6). In addition, chronic therapeutic doses do
deplete liver GSH significantly (30%; Figure 7). Futhermore, it takes more than two days
for the liver to synthesize enough GSH to bring concentrations back to normal (Figure 9).
Our model results correspond well with measurements of plasma GSH after doses of
various sizes (Figure 6).
Acetaminophen is toxic to hepatocytes because of the production of the intermediate,
NAPQI, by cytochrome P450 enzymes. Thus it is not surprising that compounds that
increase the activity of the P450 enzymes, such as caffeine [40,41] and anticonvulsant
drugs [42] also make APAPmore hepatotoxic. There is also a connection between alcohol
consumption and APAP hepatotoxicity [43], and again the presumed mechanism is an
increase in activity of one or more P450 enzymes [46,47]. We show in Figure 8 that the
effect of increasing the activity of the P450 enzymes is highly nonlinear. At low doses of
APAP there is little effect while the hepatotoxicity increases rapidly at high doses.
In Section “Effects of polymorphisms in glucoronosyl transferases” we showed that
polymorphisms in the glucoronosyl transferase enzymes can have a large effect on the
amount of liver damage caused by moderate overdoses of APAP. Figure 9 shows that
under normal circumstances, a 10 g dose does not cause much liver damage. However, if
polymorphisms in the glucoronosyI transferases reduce the Vmax values to 50% of nor-
mal then the number of hepatocytes drops to about 75% of normal after 20 hours. And,
if polymorphisms in the glucoronosyI transferases reduce the Vmax values to 10% of nor-
mal then the number of hepatocytes drops to about 10% of normal after 20 hours. Thus,
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liver damage is quite sensitive to polymorphisms in the glucoronosyl transferases and this
probably explains some of the variation in patient response.
It is known that the ability to detoxify APAP varies greatly among different animal
species [57]. In particular, cats are acutely sensitive to APAP hepatotoxicity because they
do not glucoronidate APAP well in their livers [58]. Because our model includes the
metabolic pathways in the liver, after some modifications, it can be used to study APAP
metabolism and toxicity in other species, a task that we plan to take up in the future.
The standard antidote for APAP overdoses given in Emergency Departments is N-
acetylcysteine (NAC) which is given to increase GSH production. Our model confirms
the clinical observation that NAC rescue within 8 hours of overdose is usually successful
in preventing liver failure (Figure 11). We take liver failure to be equivalent to less than
30% remaining hepatocytes as suggested in [10]. We then used the model to study dif-
ferent dosing strategies and found that modest differences result from different dosing
strategies as long as they are started early enough (Figure 12).
An important check on our model was to compare it’s predictions on patient outcomes
to the empirical data and modeling results presented in [10]. Both our model and theirs
predict accurately death or recovery in the 53 patients studied by (Figure 13). Their model,
which is much simpler than ours in that it does not contain detailed liver biochemistry, is
sufficient for predicting patient outcomes. The purpose of our larger model is to provide a
platform for experimentation with NAC dosing protocols, and with the effects of genetic
polymorphisms, expression levels of enzymes, diet, the depletion of GSH, and the effects
of environmental enzyme activators or inhibitors such as caffeine and alcohol.
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